#Amgen's anti-CD40L drug #dazodalibep has shown efficacy in a phase 3 trial in #Sjögrensdisease (SjD), raising hopes for a treatment that can alter the course of the debilitating #autoimmunedisorder.
@pharmaphorum.bsky.socialExplore
@pharmaphorum.bsky.social
@newsen.bsky.socialSjögren's Syndrome Market Expected to Grow Significantly Between 2026 and 2036 as New Therapies Emerge #USA #Las_Vegas #Telitacicept #Sjögren's_Syndrome #Dazodalibep